150 related articles for article (PubMed ID: 20421405)
1. Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
Alastruey-Izquierdo A; Cuesta I; Walther G; Cuenca-Estrella M; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2010 Jul; 54(7):3058-60. PubMed ID: 20421405
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of antifungals against Zygomycetes.
Alastruey-Izquierdo A; Castelli MV; Cuesta I; Zaragoza O; Monzón A; Mellado E; Rodríguez-Tudela JL
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():71-6. PubMed ID: 19754762
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order.
Arendrup MC; Jensen RH; Meletiadis J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7735-42. PubMed ID: 26438494
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.
Chowdhary A; Singh PK; Kathuria S; Hagen F; Meis JF
Antimicrob Agents Chemother; 2015 Dec; 59(12):7882-7. PubMed ID: 26438489
[TBL] [Abstract][Full Text] [Related]
5. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
Alastruey-Izquierdo A; Castelli MV; Cuesta I; Monzon A; Cuenca-Estrella M; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2009 Apr; 53(4):1686-9. PubMed ID: 19171801
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
8. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
9. Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species.
Al-Hatmi AM; Normand AC; Ranque S; Piarroux R; de Hoog GS; Meletiadis J; Meis JF
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795379
[TBL] [Abstract][Full Text] [Related]
10.
Leonardelli F; Macedo D; Dudiuk C; Theill L; Cabeza MS; Gamarra S; Garcia-Effron G
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30885898
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility profiles of amphotericin B and posaconazole against clinically relevant mucorales species under hypoxic conditions.
Maurer E; Binder U; Sparber M; Lackner M; Caramalho R; Lass-Flörl C
Antimicrob Agents Chemother; 2015 Feb; 59(2):1344-6. PubMed ID: 25451049
[TBL] [Abstract][Full Text] [Related]
12. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes.
Gil-Lamaignere C; Hess R; Salvenmoser S; Heyn K; Kappe R; Müller FM
J Antimicrob Chemother; 2005 Jun; 55(6):1016-9. PubMed ID: 15883179
[TBL] [Abstract][Full Text] [Related]
13. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
Manavathu EK; Abraham OC; Chandrasekar PH
Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
[TBL] [Abstract][Full Text] [Related]
14. A Revised Species Concept for Opportunistic
Wagner L; de Hoog S; Alastruey-Izquierdo A; Voigt K; Kurzai O; Walther G
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182532
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
Oakley KL; Moore CB; Denning DW
J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
Biswas C; Sorrell TC; Djordjevic JT; Zuo X; Jolliffe KA; Chen SC
J Antimicrob Chemother; 2013 Dec; 68(12):2842-6. PubMed ID: 23861311
[TBL] [Abstract][Full Text] [Related]
18. Etest cannot be recommended for in vitro susceptibility testing of mucorales.
Caramalho R; Maurer E; Binder U; Araújo R; Dolatabadi S; Lass-Flörl C; Lackner M
Antimicrob Agents Chemother; 2015; 59(6):3663-5. PubMed ID: 25845881
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
20. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
